Pierre Belichard, Enterome CEO

Nestlé puts down $40M, kicks off deal with gut mi­cro­bio­me spe­cial­ist to fight food al­ler­gies

French com­pa­ny En­terome, which works with the mi­cro­bio­me, has scored $40 mil­lion in a wide-rang­ing deal with its long-time Swiss in­vestor Nestlé Health Sci­ence to co-de­vel­op an oral pill for food al­ler­gies that’s on the cusp of en­ter­ing the clin­ic.

“To­day, we be­lieve that we have reached a lev­el where we un­der­stand what the bac­te­ria liv­ing in the hu­man gut are able to pro­duce,” said Pierre Be­lichard, CEO of En­terome.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.